Why is Hester Bios falling/rising?

As of 06-Oct, Hester Biosciences Ltd is experiencing a decline in its stock price, currently at 1,800.00, reflecting a decrease of 24.65 or 1.35%. The stock has underperformed its sector by 1.46% today and has been on a consecutive fall for the last 13 days, resulting in a total return decline of 12.71% during this period. Over the past week, the stock has dropped by 6.19%, and its year-to-date performance shows a significant decline of 24.77%, contrasting sharply with the Sensex, which has gained 4.67% in the same timeframe. Despite reporting a growth in net profit of 145.1% and positive results for the last five consecutive quarters, the company faces challenges such as a high Debt to EBITDA ratio of 3.49 times and poor long-term growth rates, which contribute to investor concerns.
Broader market context indicates that Hester Bios has significantly underperformed compared to the benchmark, with a one-year return of -23.00% against the BSE500's negative return of -1.93%. This stark contrast highlights the stock's struggles in attracting investor confidence, as evidenced by the negligible domestic mutual fund holdings, suggesting a lack of comfort with the stock's current valuation. The stock's trading below its moving averages further indicates a bearish sentiment, compounded by liquidity concerns despite a recent rise in delivery volume. Overall, while the company has shown positive financial results, the prevailing negative factors and market performance have led to the stock's recent decline.